2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Abstract Number: 931

Ultra-Low Doses of Rituximab for Retreatment of RA: A Randomized Controlled Non-Inferiority Trial
Abstract Number: 2672

Ultrasonography in the Diagnosis of Giant Cell Arteritis
Abstract Number: 1448

Ultrasonography of Major Salivary Glands in Primary Sjögren’s Syndrome: Identification of Distinct Evolving Patterns in the Long-Term Follow-up
Abstract Number: 297

Ultrasound and Magnetic Resonance Imaging Evaluation of the Fingers’ Joints of Psoriatic Arthritis Patients – Interim Analysis
Abstract Number: 898

Ultrasound Demonstrates Rapid Reduction of Crystal Depositions During a Treat-to-target Approach in Gout Patients: Two-year Results from a Longitudinal, Observational Study (NOR-GOUT)
Abstract Number: 2607

Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis
Abstract Number: 287

Ultrasound Evaluation of the Achilles Enthesis in Inflammatory and Non-inflammatory Processes: A Systematic Review
Abstract Number: 711

Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints
Abstract Number: 1360

Ultrasound Guided Synovial Biopsies Safely Aid in the Assessment of Inflammatory Arthritis
Abstract Number: 282

Ultrasound Is More Sensitive Compared to Conventional Radiography to Detect Joint Erosions in ACPA-positive Patients with Musculoskeletal Pain
Abstract Number: 721

Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease
Abstract Number: 2644

Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis
Abstract Number: 280

Ultrasound versus Conventional Treat-To-Target Strategies in Early Rheumatoid Arthritis: Magnetic Resonance Imaging Outcome Data from a 2-year Randomized Controlled Strategy Trial
Abstract Number: 78

Ultraviolet Light Induces Increased T Cell Activation in Lupus-Prone Mice via Type I Interferon-Dependent Inhibition of T Regulatory Cells
Abstract Number: 796

Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort
Abstract Number: 1144

Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis
Abstract Number: 2083

Understanding Knee Function and Symptom Management in Individuals with Risk Factors for Knee Osteoarthritis
Abstract Number: 2037

Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity
Abstract Number: 568

Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Abstract Number: 367

Understanding the Mystery of Sarcoidosis: An Academic Rheumatology Center Experience
Abstract Number: 2251

Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study
Abstract Number: 435

Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower
Abstract Number: 18

Undifferentiated Connective Tissue Disease at Risk for SSc: Potential Role of Circulating CXCL-10, CXCL-11 and IL-33 in Predicting Disease Evolution
Abstract Number: 79

Unique Primed Status of Microglia Under the Systemic Autoimmune Condition of Lupus-Prone Mice
Abstract Number: 1332

United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Abstract Number: 2479

Unmet Treatment Needs in Patients with Psoriatic Arthritis
Abstract Number: 513

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Abstract Number: 518

Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Abstract Number: 551

Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis
Abstract Number: 1219

Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population
Abstract Number: 1037

Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis
Abstract Number: 2570

Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Abstract Number: 2629

Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Abstract Number: 690

Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment
Abstract Number: 1918

Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis
Abstract Number: 2637

Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis
Abstract Number: 1118

US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation
Abstract Number: 549

US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey
Abstract Number: 2059

Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases
Abstract Number: 2394

Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Abstract Number: 1861

Use of a Novel Electronic Auto-notification Process to Manage Transitions of Care in Rheumatic Patients on DMARD Therapy
Abstract Number: 161

Use of a Systematic Consensus Process to Inform Development of the Veterans Health Affairs Simulation Learning, Education and Research Network (SimLEARN) Musculoskeletal Clinician Course
Abstract Number: 2462

Use of Complementary and Alternative Medicine (CAM) in a Psoriatic Arthritis Cohort
Abstract Number: 2412

Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis
Abstract Number: 1672

Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018
Abstract Number: 370

Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features
Abstract Number: 2832

Using a Learning Collaborative to Develop an RA Disease Activity Communication Tool to Promote Shared Decision-Making in Treat to Target
Abstract Number: 1860

Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study
Abstract Number: 2410

Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable
Abstract Number: 1906

Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)
Abstract Number: 1246

Using PROMIS Data to Assess Activity of Inflammatory Eye Disease
Abstract Number: 1539

Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study
Abstract Number: 1837

Ustekinumab for the Treatment of Giant Cell Arteritis
Abstract Number: 662

Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Abstract Number: 407

Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis
Abstract Number: 1165

Utility of Coronary Calcium Scoring (CCS) in the Spectrum of Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis – a Systematic Review
Abstract Number: 212

Utility of Mood Disorders Questionnaire in Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry
Abstract Number: 303

Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission
Abstract Number: 1802

Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics
Abstract Number: 665

Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia
Abstract Number: 1361

Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Abstract Number: 1210

Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Abstract Number: 2711

Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 1762

UV Light Induces Acute Type I Interferon Production in the Skin and Blood Which Is cGAS Dependent
Abstract Number: 81

UV Light Stimulates a Systemic Neutrophil Response Associated with Transient Kidney Injury
Abstract Number: 2481

Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].